Glycolysis stands as a fundamental metabolic pathway, universally employed by cells to oxidize glucose. This process is critical for generating energy in the form of ATP (Adenosine triphosphate) and producing essential metabolic intermediates utilized in various cellular processes. Beyond glucose, other hexose sugars like fructose and galactose are also metabolized through the glycolytic pathway[1]. Understanding where glycolysis occurs is key to grasping its role in cellular energy production.
Delving into the Fundamentals: The Cytoplasmic Location of Glycolysis
Glycolysis takes place in the cytoplasm, also known as the cytosol, of cells. Here, a single six-carbon molecule of glucose undergoes oxidation, resulting in two three-carbon molecules of pyruvate. The subsequent fate of pyruvate is determined by the presence of mitochondria and oxygen availability within the cell. Mitochondria are the primary sites of oxygen consumption and ATP generation through the electron transport chain. In cells equipped with mitochondria, pyruvate undergoes decarboxylation via the pyruvate dehydrogenase complex, transforming into Acetyl-CoA. This molecule then enters the Tricarboxylic acid cycle, ultimately contributing to ATP production.
However, under conditions of oxygen scarcity (anaerobic conditions) or in cells lacking mitochondria, anaerobic glycolysis becomes the dominant pathway. In this scenario, pyruvate is reduced to lactate, with NADH being reoxidized to NAD+ by lactate dehydrogenase. This anaerobic process is a vital ATP source for cells devoid of mitochondria, such as erythrocytes (red blood cells). During aerobic glycolysis, NADH, generated during glycolysis, is shuttled into the mitochondria via the malate-aspartate shuttle or glycerol phosphate shuttle. Within the mitochondria, it is reoxidized to NAD+ while participating in the electron transport chain for ATP production[1, 2].
Glycolysis at the Cellular Level: A Cytoplasmic Ten-Step Pathway
Aerobic glycolysis is a meticulously orchestrated sequence of reactions occurring in the cytoplasm, where oxygen plays an indirect role by enabling the reoxidation of NADH to NAD+. This ten-step pathway initiates with a glucose molecule and culminates in the production of two pyruvate molecules[1]. Each step is catalyzed by specific enzymes within the cytoplasm:
Step 1: Upon entering the cell’s cytoplasm, glucose is immediately phosphorylated by the enzyme hexokinase, or glucokinase in liver and pancreatic beta cells. ATP hydrolysis provides the phosphate for this reaction, converting glucose to glucose-6-phosphate. This irreversible step effectively traps glucose within the cell’s cytoplasm. Hexokinase exhibits broad specificity, phosphorylating various six-carbon sugars, while glucokinase is specific to glucose.
Step 2: Glucose-6-phosphate (an aldose) is isomerized into fructose-6-phosphate (a ketose) by phosphoglucose isomerase in the cytoplasm. This reaction is readily reversible.
Step 3: In a crucial regulatory step within the cytoplasm, fructose-6-phosphate is phosphorylated to fructose-1,6-bisphosphate by phosphofructokinase-1 (PFK1). This irreversible and rate-limiting step is also the second ATP-consuming step in glycolysis, committing the molecule to the glycolytic pathway.
Step 4: Fructose-1,6-bisphosphate is cleaved in the cytoplasm into dihydroxyacetone phosphate (DHAP) and glyceraldehyde-3-phosphate (G3P) by aldolase. This reversible reaction is not regulated. Liver aldolase B can also cleave fructose-1-phosphate during fructose metabolism.
Step 5: Triose phosphate isomerase, found in the cytoplasm, catalyzes the interconversion of DHAP and glyceraldehyde-3-phosphate. This isomerization ensures that both products of step 4 can proceed through the rest of glycolysis, effectively yielding two molecules of glyceraldehyde-3-phosphate.
Step 6: Glyceraldehyde-3-phosphate dehydrogenase, located in the cytoplasm, catalyzes the oxidation of glyceraldehyde-3-phosphate, leading to the formation of 1,3-bisphosphoglycerate. This is the first oxidation-reduction reaction of glycolysis. NAD+ is reduced to NADH, and the aldehyde group of glyceraldehyde-3-phosphate is oxidized to a carboxyl group, which is then phosphorylated. The limited availability of NAD+ in the cytoplasm necessitates the reoxidation of NADH back to NAD+.
Step 7: The first ATP-generating step in glycolysis occurs in the cytoplasm with the formation of 3-phosphoglycerate from 1,3-bisphosphoglycerate (1,3-BPG). Phosphoglycerate kinase facilitates the transfer of the phosphate group from 1,3-BPG to ADP, generating ATP. This substrate-level phosphorylation produces 2 ATP molecules. Additionally, some 1,3-BPG is converted to 2,3-bisphosphoglycerate (2,3-BPG) by bisphosphoglycerate mutase in red blood cells, a molecule important for oxygen delivery.
Step 8: Phosphoglycerate mutase, in the cytoplasm, catalyzes the reversible isomerization of 3-phosphoglycerate to 2-phosphoglycerate, shifting the phosphate group from carbon 3 to carbon 2.
Step 9: 2-phosphoglycerate is dehydrated to phosphoenolpyruvate in the cytoplasm. Phosphoenolpyruvate contains a high-energy enol phosphate bond.
Step 10: The final step of glycolysis, occurring in the cytoplasm, involves pyruvate kinase-catalyzed conversion of phosphoenolpyruvate to pyruvate. This irreversible substrate-level phosphorylation generates 2 ATP molecules.
Following glycolysis in the cytoplasm, pyruvate can proceed through aerobic respiration in the mitochondria or anaerobic fermentation in the cytoplasm to form lactic acid. Regardless of the subsequent pathway, glycolysis itself results in a net gain of two ATP molecules per glucose molecule in the cytoplasm.
Regulatory Mechanisms within the Cytoplasm: Fine-Tuning Glycolysis
The regulation of glycolysis, occurring within the cytoplasm, is crucial for maintaining cellular energy homeostasis. This regulation is achieved through covalent modification of rate-limiting enzymes, allosteric modulation, and hormonal control, all acting within the cytoplasmic environment.
A bifunctional enzyme, PFK2/Fructose bisphosphatase, plays a key role in allosteric regulation in the cytoplasm. Fructose-2,6-bisphosphate (F2,6-BP) is a potent allosteric effector whose concentration is dictated by the insulin/glucagon ratio. PFK1, a key glycolytic enzyme, is positively regulated by F2,6-BP. PFK-2, the kinase domain of the bifunctional enzyme, catalyzes F2,6-BP synthesis. High insulin levels, indicative of abundant substrates, activate a protein phosphatase in the cytoplasm. This phosphatase dephosphorylates PFK2, activating its kinase activity and promoting glycolysis.
Conversely, elevated glucagon levels trigger a cAMP increase, activating protein kinase A. This kinase favors the phosphorylated form of the bifunctional enzyme. Phosphorylation inactivates PFK2 while activating the phosphatase domain, leading to decreased F2,6-BP levels and inhibiting glycolysis in the cytoplasm, favoring gluconeogenesis.
Hormonal control significantly impacts cytoplasmic glycolysis. Increased glucose levels following carbohydrate consumption trigger insulin release, elevating the insulin/glucagon ratio. Insulin activates glucokinase, PFK1, and pyruvate kinase in the cytoplasm – the key enzymes catalyzing irreversible glycolytic steps – to process the available glucose. Simultaneously, low glucagon levels suppress gluconeogenesis. Long-term control via gene transcription is critical during fasting, starvation, and diabetes when the insulin/glucagon ratio is low. Under these conditions, the synthesis of glucokinase, PFK1, and pyruvate kinase is reduced by modulating gene transcription[1, 3, 1].
Clinical Significance of Cytoplasmic Glycolysis: Implications for Health and Disease
Dysregulation of glycolysis within the cytoplasm has significant clinical implications, impacting various health conditions:
Glucokinase Deficiency: Both glucokinase and hexokinase, cytoplasmic enzymes, phosphorylate glucose to glucose-6-phosphate. However, they differ in location and glucose affinity. Glucokinase is primarily in the liver and pancreatic beta cells, while hexokinase is in other tissues. Glucokinase has lower glucose affinity and functions mainly when glucose levels are high, directing glucose towards glycogen synthesis in the liver after meals. Hexokinase, with higher affinity, prioritizes glucose for immediate cellular needs when glucose levels are low. In pancreatic beta cells, glucokinase acts as a glucose sensor, regulating glucose entry and glycolysis to maintain blood glucose homeostasis. Heterozygous inactivating glucokinase mutations cause maturity-onset diabetes of the young type 2 (MODY2 or GCK-MODY)[4, 5]. Homozygous mutations result in neonatal diabetes mellitus[6, 7, 8].
2,3-Bisphosphoglycerate (2,3-BPG): Human red blood cells (erythrocytes) normally maintain low 2,3-BPG levels in their cytoplasm. During oxygen deprivation, such as at high altitudes or in respiratory diseases like asthma and COPD, the cytoplasmic conversion of 1,3-BPG to 2,3-BPG by bisphosphoglycerate mutase increases. 2,3-BPG preferentially binds to deoxyhemoglobin, stabilizing its T-state and promoting oxygen release to tissues. This shifts the oxygen dissociation curve to the right[9].
Pyruvate Kinase Deficiency: Autosomal recessive pyruvate kinase deficiency, stemming from PKLR gene mutations, affects the final cytoplasmic step of glycolysis. Pyruvate kinase produces ATP while forming pyruvate. Mature red blood cells lack mitochondria, making them highly vulnerable to pyruvate kinase deficiency as glycolysis is their sole ATP source. ATP is crucial for maintaining RBC membrane integrity. Deficiency compromises membrane integrity, leading to hemolysis, reduced oxygen delivery, fatigue, and shortness of breath. Hemoglobin release and breakdown elevate bilirubin levels. Damaged cell membranes result in echinocytes (spiculated RBCs). Reduced RBC count triggers reticulocyte appearance. However, hepatocyte pyruvate kinase isozyme deficiency is less impactful due to mitochondrial ATP production. 2,3-BPG levels rise as a compensatory mechanism to enhance oxygen delivery, despite not generating ATP[10].
Pyruvate Kinase Role in Cancer:
Pyruvate kinase, particularly the M2 isoform, is upregulated in highly proliferative cells like embryonic and cancer cells. Cancer cell survival depends on metabolic reprogramming. While normal cells under aerobic conditions direct pyruvate from cytoplasmic glycolysis to mitochondria for energy generation, tumor cells favor aerobic glycolysis (Warburg effect). In this phenomenon, even with oxygen and mitochondria present, pyruvate is diverted to lactate production in the cytoplasm. This metabolic switch, known as the Warburg effect, provides cancer cells with rapid energy production and biosynthetic precursors. The M2 isoform of pyruvate kinase is often upregulated in cancer cells[11, 12, 13].
The reasons behind enhanced aerobic glycolysis in cancer cells are still being elucidated. Hypotheses include rapid ATP generation through lactate production, increased signal transduction, enhanced flux towards biosynthetic pathways, and lactate-induced acidic microenvironment favoring invasiveness and metastasis [14, 15, 16]. Understanding where glycolysis occurs and its regulation in both normal and diseased cells is crucial for developing targeted therapies.
Review Questions
[To be added – consider questions relevant to location and regulation]
References
1.Dashty M. A quick look at biochemistry: carbohydrate metabolism. Clin Biochem. 2013 Oct;46(15):1339-52. [PubMed: 23680095]
2.Niu X, Arthur P, Abas L, Whisson M, Guppy M. Carbohydrate metabolism in human platelets in a low glucose medium under aerobic conditions. Biochim Biophys Acta. 1996 Oct 24;1291(2):97-106. [PubMed: 8898869]
3.Rui L. Energy metabolism in the liver. Compr Physiol. 2014 Jan;4(1):177-97. [PMC free article: PMC4050641] [PubMed: 24692138]
4.Tattersall RB. Mild familial diabetes with dominant inheritance. Q J Med. 1974 Apr;43(170):339-57. [PubMed: 4212169]
5.Osbak KK, Colclough K, Saint-Martin C, Beer NL, Bellanné-Chantelot C, Ellard S, Gloyn AL. Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia. Hum Mutat. 2009 Nov;30(11):1512-26. [PubMed: 19790256]
6.Froguel P, Vaxillaire M, Sun F, Velho G, Zouali H, Butel MO, Lesage S, Vionnet N, Clément K, Fougerousse F. Close linkage of glucokinase locus on chromosome 7p to early-onset non-insulin-dependent diabetes mellitus. Nature. 1992 Mar 12;356(6365):162-4. [PubMed: 1545870]
7.Hattersley AT, Turner RC, Permutt MA, Patel P, Tanizawa Y, Chiu KC, O’Rahilly S, Watkins PJ, Wainscoat JS. Linkage of type 2 diabetes to the glucokinase gene. Lancet. 1992 May 30;339(8805):1307-10. [PubMed: 1349989]
8.Froguel P, Zouali H, Vionnet N, Velho G, Vaxillaire M, Sun F, Lesage S, Stoffel M, Takeda J, Passa P. Familial hyperglycemia due to mutations in glucokinase. Definition of a subtype of diabetes mellitus. N Engl J Med. 1993 Mar 11;328(10):697-702. [PubMed: 8433729]
9.Benesch R, Benesch RE. The effect of organic phosphates from the human erythrocyte on the allosteric properties of hemoglobin. Biochem Biophys Res Commun. 1967 Jan 23;26(2):162-7. [PubMed: 6030262]
10.Grace RF, Zanella A, Neufeld EJ, Morton DH, Eber S, Yaish H, Glader B. Erythrocyte pyruvate kinase deficiency: 2015 status report. Am J Hematol. 2015 Sep;90(9):825-30. [PMC free article: PMC5053227] [PubMed: 26087744]
11.WARBURG O. On the origin of cancer cells. Science. 1956 Feb 24;123(3191):309-14. [PubMed: 13298683]
12.Mazurek S, Boschek CB, Hugo F, Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol. 2005 Aug;15(4):300-8. [PubMed: 15908230]
13.Christofk HR, Vander Heiden MG, Wu N, Asara JM, Cantley LC. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature. 2008 Mar 13;452(7184):181-6. [PubMed: 18337815]
14.Gupta V, Wellen KE, Mazurek S, Bamezai RN. Pyruvate kinase M2: regulatory circuits and potential for therapeutic intervention. Curr Pharm Des. 2014;20(15):2595-606. [PubMed: 23859618]
15.Olson KA, Schell JC, Rutter J. Pyruvate and Metabolic Flexibility: Illuminating a Path Toward Selective Cancer Therapies. Trends Biochem Sci. 2016 Mar;41(3):219-230. [PMC free article: PMC4783264] [PubMed: 26873641]
16.Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004 Nov;4(11):891-9. [PubMed: 15516961]
